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Background: Some high-risk (HR) mental states for psychosis may lack diagnostic specificity and predictive value.
Furthermore, psychotic-like experiences found in young populations may act not only as markers for psychosis but
also for other non-psychotic psychiatric disorders. A neglected consideration in these populations is the effect of
substance misuse and its role in the development of such mental states or its influence in the evolution toward
full psychotic presentations. Therefore, the main aim of this study was to thoroughly describe past and current
substance use profiles of HR individuals by comparing a consecutive cohort of young people at high risk referred to
a population-based early intervention clinical service with a random sample of healthy volunteers (HV) recruited
from the same geographical area.
Methods: We compared alcohol and substance use profiles of sixty help-seeking HR individuals and 60 healthy
volunteers (HV). In addition to identification of abuse/dependence and influence on psychotic-like experiences,
differences between HR individuals and HV were assessed for gender, ethnicity, occupational status, age of lifetime
first substance use, prevalence and frequency of substance use.
Results: There were no cases of substance use disorder or dependence in either groups. HR individuals were
significantly younger than HV when they first started to use substances (p = 0.014). The prevalence of overall HR
substance use was similar to that of HV. Although HR individuals reported less cannabinoid use than HV currently
(15% vs. 27%), and more in the past (40% vs. 30%), the differences were not statistically significant (p = 0.177 &
0.339 respectively). Current frequency of use was significantly higher for HR individuals than HV for alcohol
(p = 0.001) and cannabinoids (p = 0.03). In this sample, only 5% of HR individuals converted to psychosis over a
two-year follow-up.
Conclusions: Certain profiles of substance use could potentially play a significant part in the evolution of HR
presentations. Therefore, substance use may well represent a clinical domain that requires further emphasis and
more detailed consideration in future studies.
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It is noteworthy that overall transition rates reported in
different cohorts of individuals at clinical high-risk for
psychosis (HR) have consistently declined over the last
decade [1]. Also, conversion rates have varied across dif-
ferent centers world-wide [1,2]. These discrepancies have
been associated with a variety of factors. For example, it
has been suggested that the ultimate level of current* Correspondence: dr335@medschl.cam.ac.uk
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unless otherwise stated.conversions may not be so low or diverse if high risk in-
dividuals were monitored for both longer and compar-
able follow-up periods [2]. In addition, early detection
might indirectly involve provision of non-specific clinical
care. Supportive therapy and/or pharmacological inter-
ventions, including antidepressants or anxiolytics could
reduce stress and subsequently, the likelihood of conver-
sion into frank psychotic disorders. Also, by detecting
this group earlier some recent cohorts may have included
more false positives than previous studies. In other words,
early detection of these mental states may also identify HR
phenotypes that could eventually take different diagnostichis is an Open Access article distributed under the terms of the Creative
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psychosis may lack diagnostic specificity and predictive
value. In fact, presence of psychotic-like symptoms in
young people with disorders of anxiety and depression is
more prevalent than previously considered [3,4]. Further-
more, psychotic-like experiences found in adolescent pop-
ulations may act not only as markers for psychosis but
also for other non-psychotic psychiatric disorders [5].
Notably, none of these hypotheses have considered the
effect of substance misuse in HR individuals and its role
in the development of such mental states or its influence
in the evolution toward full psychotic presentations. This
seems particularly pertinent as alcohol and drug misuse
is common among people with psychotic illnesses, includ-
ing those suffering from a first-episode, and significantly
more prevalent than in the general population [6-8].
Moreover, the abuse of illicit substances, such as cannabis,
has been positively associated with the development of
psychotic disorders [9,10]. A recent literature review sug-
gested that increased rates of substance misuse in HR in-
dividuals may be associated with transitions to psychosis.
However, it was also highlighted that this evidence was
limited by the low number of studies that considered this
variable, variety of results and scarce information regard-
ing change of patterns of use over time. Moreover, the vast
majority of studies evaluated in this review neither re-
corded alcohol misuse nor included a comparative group
of representative healthy volunteers (HV) in order to
better determine possible differences with regard to sub-
stance use habits in those individuals at HR [11].
This review also revealed that only diagnostic struc-
tured interviews were employed to assess substance use.
These tools exclusively focus on the identification of sub-
stance abuse and/or dependence [11]. Therefore, it would
be preferable to employ a tool to accurately measure alco-
hol and drug use and enable a complete evaluation of sub-
stance use that does not necessarily reach the category of
dependence and/or abuse.
Given the paucity of studies primarily addressing the
impact of alcohol and drug misuse in HR populations,
the main aim of this study was to thoroughly describe
past and current substance use profiles of HR individuals
by comparing a consecutive cohort of young people at
HR referred to a population-based early intervention clin-
ical service with a random sample of HV recruited from
the same geographical area.
Methods
Setting
CAMEO (http://www.cameo.nhs.uk) is an early inter-
vention in psychosis service which offers management
for people aged 14-35 years suffering from first-episode
psychosis in Cambridgeshire, UK. CAMEO also accepts
referrals of people at HR. Referrals are accepted frommultiple sources including general practitioners, other
mental health services, school and college counselors,
relatives and self-referrals [12].
Sample
A consecutive cohort of 60 help-seeking individuals,
aged 16-35, referred to CAMEO from February 2010 to
September 2012 met criteria for HR, according to the
Comprehensive Assessment of At Risk Mental States
(CAARMS) [13]. In our sample, all individuals fulfilled
criteria for the attenuated psychotic symptoms group.
Seven individuals (11.7%) also qualified for the vulnerabil-
ity traits group. The only exclusion criteria were confirmed
intellectual disability (Wechsler Adult Intelligence Scale –
tested IQ <70), or prior total treatment with antipsychotics
for more than one week.
During the same period (February 2010-September
2012), a random sample of 60 HV was recruited by post,
using the Postal Address File (PAF®) provided by Royal
Mail, UK. To ensure that each HR and HV resided in
the same geographical location, 50 corresponding post-
codes, matching the first 4/5 characters and digits of
each recruited HR individual (e.g. PE13 5; CB5 3), were
randomly selected using Microsoft SQL Server, a rela-
tional database management system, in conjunction with
the PAF database. Each of these 50 addresses was sent a
recruitment flyer containing a brief outline of the study,
inclusion criteria and contact details. If this failed to gen-
erate recruits, a consecutive sample of postcodes was
selected. This process was repeated until a match was re-
cruited. HV interested in the study could only participate
if they were aged 16-35, resided in the same geographical
area as HR individuals (Cambridgeshire), and did not have
previous contact with mental health services.
Ethical approval
Ethical approval was granted by the Cambridgeshire East
Research Ethics Committee.
Measures
Sociodemographic information (age, gender, ethnicity
and occupational status) was collected for all individuals.
HR individuals were interviewed by senior trained psychi-
atrists working in CAMEO, using the Mini International
Neuropsychiatric Interview (MINI), Version 6.0.0 [14], a
brief structured diagnostic interview for DSM-IV Axis I
psychiatric disorders.
The Positive and Negative Syndrome Scale (PANSS)
[15] for psychotic symptoms was also employed to
capture the severity of positive symptoms (7 items),
negative symptoms (7 items) and general psychopath-
ology (16 items) in a 7-point scale, with higher scores
indicating greater severity of illness. These assessments




HR (n = 60) HV (n = 60) p-values









Male 31 (51.7%) 26 (43.3%) 0.465~
Female 29 (48.3%) 34 (56.7%) 0.465~
Ethnicity (n, %)†
White 56 (93.3%) 55 (91.7%) 1.000~
Mixed 2 (3.3%) 2 (3.3%) 1.000~
Asian 1 (1.7%) 2 (3.3%) 1.000~
Black 1(1.7%) 1(1.7%) 1.000~
Occupational status
(n, %) (7)‡
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administer each of the measurement tools.
A novel substance use tool was used to record the
specific type of drug and categorised it according to
chemical constituents; these comprised sedatives, hallu-
cinogens, dissociatives, cannabinoids, stimulants, opi-
ates, solvents, alcohol and other substances (e.g. legal
highs). Frequency was measured using 8 categories:
never, one off, less than once a month, once a month,
once or twice a week, 3-6 times a week, daily use and
uncertain frequency. Quantity measures were excluded
as they could lack validity due to the possible inaccur-
acy in self-reports of drug purity, variety and the size of
drug doses. Age at first use was also recorded as age of
first substance use has been found to predate initial
psychotic symptoms by several years [8,10] and has
been associated with the onset of prodromal symptoms
[10,16]. It has been suggested that individuals may
use substances to self-medicate following the onset of
psychotic symptoms [17]. Conversely, it has been ar-
gued that substance misuse might cause psychotic
symptoms or increase the likelihood of psychotic
symptoms in already vulnerable individuals [10,18,19].
Therefore, questions were added to capture a) whether
any unusual experiences were experienced under the
influence of drugs or alcohol and b) whether drugs or
alcohol were used to relieve any unusual symptoms.
Individuals were asked about their current drug and al-
cohol use (now and within the last 3 months) and their
greatest past use (period of time prior to the last three
months when drug and alcohol use was at its greatest).
It was not possible to discern the extent to which indi-
viduals deny or exaggerate alcohol and drug use. To
minimise this, participants were assessed during a face
to face interview which took place over several sessions.
This provided confidentiality and enabled the inter-
viewer to build a rapport with the participant, both of
which have been shown to increase the validity of self-
report [20].Unemployed 20 (33.3%) 8 (13.%) 0.004~
Employed 8 (13.3%) 27 (45.0%) 0.001~
Students 25 (41.7) 25 (41.7) 0.575~
‘P- values’ * = t-test ~ = Fisher’s exact.
† ‘White ethnicity’ refers to subjects who are White British, White Irish, or other
White backgrounds.
‘Mixed ethnicity’ refers to those who are White and Black Caribbean, mixed
White and Black African, mixed White and Asian, or any other
mixed backgrounds.
‘Asian ethnicity’refers to those who are Indian or Chinese.
‘Black ethnicity’ refers to subject from any Black backgrounds.
‡ Occupational status is broadly categorized into 3 groups.
‘Unemployed’ includes subjects who do not have a job, either they are looking
for work, not looking for work (e.g., housewife), or not being able to work due
to medical reasons.
‘Employed’refers to people who have full/part-time employment, or employed
but currently unable to work.
‘Students’ refers to full/part-time students, including those who are also
working some hours.Statistical analysis
Differences between HR individuals and HV were assessed
using two sample t-test for approximately normally dis-
tributed continuous variables (age) and Fisher’s exact test
for categorical variables (gender, ethnicity and occupa-
tional status). Fisher’s exact test was also used for asses-
sing the differences between substance use distributions
and patterns as this is more appropriate for smaller
sample sizes. Wilcoxon signed rank test was employed for
non-normally distributed continuous variables (age of
lifetime first substance use, frequency of substance use).
Boxplots were used for graphical representation of the
differences in frequency of substance use.Results
Sociodemographic profile
Sociodemographic information was collected, compris-
ing age, gender, ethnicity and occupational status. Table 1
shows a comparison between HR and HV individuals.
There was a difference in age between the two groups;
HV were significantly older than the HR individuals (22.6
SD = 5.7 vs. 19.9 SD = 2.4; p = < 0.001). The HR group had
a slightly higher proportion of males and the HV group
had a slightly higher proportion of females. Both groups
were predominantly white with a similar proportion of
Mixed, Asian and Black participants. Both groups con-
tained the same number of students (41.7%), but signifi-
cantly more HV were employed (p = 0.001).
Psychiatric diagnoses and PANSS scores
We obtained MINI DSM-IV diagnoses for 55 of the 60
HR individuals. Thirty Eight (69.1%) had more than one
DSM-IV psychiatric diagnosis, mainly within the affective
and anxiety diagnostic spectra. Primary diagnoses for this
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current or recurrent (n = 26; 47.3%) > social phobia (n = 7;
12.7%) = generalised anxiety disorder (n = 7; 12.7%) >
obsessive compulsive disorder (n = 5; 9.1%) > bipolar dis-
order, type II (n = 2; 3.6%) > panic disorder (n = 1; 1.8%) =
posttraumatic stress disorder (n = 1; 1.8%). Six HR individ-
uals (10.9%) did not fulfill sufficient criteria for a DSM-IV
Axis I diagnosis. None of the participants had a substance
use disorder. The study protocol did not routinely admin-
ister a MINI for HV. However, if the information elicited
with the substance use questionnaire indicated that sub-
stance use was approaching the threshold for abuse or
dependence the protocol was to administer a MINI for
verification. This was not the case for any of the HV.
The mean PANSS scores for the HR group comprised
positive symptoms (13.1, SD = 3.2), negative symptoms
(12.4, SD = 5.0) and general psychopathology (32.7, SD =
7.0). These scores indicated a “mildly ill” group with
regards to psychotic symptoms [21]. Psychotic symp-
toms for the HV group were subclinical: 7.1 (SD = 0.4)
for positive symptoms, 7.8 (SD = 0.8) for negative symp-
toms and 16.4 (SD = 1.3) for general psychopathology.
Substance use
Distribution of substance use
Table 2 shows the number and percentages of individ-
uals who were using each of the substances at the time
of their referral to CAMEO. Alcohol and cannabinoids
were the most prevalent for both the HR and HV groups.
Table 3 shows how many of the HR and HV individuals
were not using any substances, using only one substance
(mono-drug) and more than one substance (poly-drug)
currently and in the past. Interestingly, more HR individ-
uals (52%) than HV (12%) indicated that they did not use
any substance currently (p = 0.001). Although 42% of HR
individuals and 32% of HV abstained from using any
substance in the past, this difference was not statistically
significant (p = 0.343). A significantly higher proportion of
HV disclosed that they were currently using one substance
(58% vs. 32%, p = 0.006) but not poly substances (30% vs.Table 2 Substance use distribution in HV and HR
individuals at the time of referral to CAMEO
HR(n) % HV(n) % p-value*
Alcohol 18 30.0 31 51.6 0.025
Cannabinoids 9 15.0 16 26.6 0.177
Dissociatives 1 1.6 0 - 1
Hallucinogens 3 5 4 6.6 1
Opiates 1 1.6 0 - 1
Sedatives 1 1.6 0 - 1
Stimulants 6 6 4 6.6 0.743
P- values: * = Fisher’s exact.17%, p = 0.131). Similarly, more HV individuals reported
using only one substance in the past (p = 0.028). However,
the percentage of past poly-drug users was higher for HR
individuals (38% vs. 28%), although statistical significance
was not reached (p = 0.333).
Age of lifetime first substance use
When considering all substances, the median age of HR
individuals was 13 (SD = 2.2) and 15 (SD = 3.7) for HV.
Results of a Wilcoxon signed-rank test revealed that HR
individuals were significantly younger than HV when
they first started to use substances (p = 0.014). When ex-
cluding alcohol, the finding was in the same direction
(14, SD = 1.58 vs.16, SD = 2.7; p = 0.020). This suggests
that for both groups, initial alcohol consumption hap-
pened 1-2 years before drug use commenced.
Current prevalence of substance use
Alcohol and cannabinoids were the most prevalent choice
of substance for mono-drug and poly-drug users for both
groups. Of the 19 HR individuals that reported currently
using only one substance 95% used just alcohol and 5%
used just cannabinoids. However, 100% of the 13 HV
current mono-drug users reported using only alcohol.
Table 4 outlines how many of the 10 HR and 18 HV
current poly-drug users endorsed the use of each category
of substance. Alcohol, cannabinoids and stimulants were
the most likely substances of choice for HR poly-drug
users; for HV, it was alcohol and cannabinoids. These find-
ings suggest that HR poly-drug users experimented with a
wider range of substances than HV poly-drug users.
Past prevalence of substance use
For both HR and HV individuals, there was a wider
range of substances used in the past. A higher proportion
of HV (40%) reported past mono use of substances when
compared with HR mono-drug users (20%, p = 0.028). In
addition to alcohol and cannabinoids, HR mono-drug
users also experimented with hallucinogens and stimu-
lants and HV mono-drug users with cannabinoids and
opiates.
For past poly use of substances, the number of HR in-
dividuals reporting use for each substance was higher
with the exception of opiates, which was the same. How-
ever, none of the differences reached statistical significance
(see table 4). There was also an increase in the range of
substances for poly-drug use. Hallucinogens, dissociatives
and stimulants were additions for HV compared to disso-
ciatives, sedatives and opiates for HR individuals.
When combining mono-drug and poly-drug users,
current alcohol use was similar with 47% of HR individ-
uals and 52% of HV endorsing use (p = 0.715). Similarly,
there was no significant difference in the amount of alco-
hol use disclosed by HV (65%) and HR individuals (48%,
Table 3 Substance use pattern in HR and HV individuals
Current Past
HR(n) % HV(n) % p value* HR(n) % HV(n) % p-value*
No 31 52 7 12 <0.001 25 42 19 32 0.343
Mono-drug 19 32 35 58 0.006 12 20 24 40 0.028
Poly-drug 10 17 18 30 0.131 23 38 17 28 0.333
P- values: * = Fisher’s exact.
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in current and past use. Fewer HR individuals acknowl-
edged cannabinoid use than HV at the time of their refer-
ral to CAMEO (15% vs. 27%), but more HR individuals
endorsed use in the past (40% vs. 30%). However, these
differences were not statistically significant (p = 0.177 &
0.339 respectively).Frequency of substance use
Figure (1a) shows the frequency of current use for the
most prominent substances. The median frequency of
use was significantly higher for HR individuals than HV
for alcohol (p = 0.001) and cannabinoids (p = 0.03), but
not for hallucinogens (p = 0.386) and stimulants (p =
0.593). Combined with the previous results, this indi-
cates that although the proportion of HV that drank al-
cohol and use cannabinoids was higher in general, HR
individuals used these substances more frequently.
Figure (1b) shows the frequency of past use for the
most prominent substances. There were no significant
differences in past frequency of use for any of the sub-
stances with the exception of hallucinogens. HV used
hallucinogens significantly more often than HR individ-
uals (p = 0.037). This suggests that frequency of sub-
stance use for HR individuals remained similar for
current and past use; whereas HV were more likely to
have a period in the past where they used hallucinogens
more frequently.Table 4 Number of HR and HV individuals that endorsed usin
poly-drug use
Current










Alcohol 18 13 0.404 10 18 0.13
Cannabinoids 1 0 1 8 16 0.10
Dissociatives 0 0 1 1 0 1
Hallucinogens 0 0 1 3 4 1
Opiates 0 0 1 1 0 1
Sedatives 0 0 1 1 0 1
Stimulants 0 0 1 6 4 0.74
P- values: * = Fisher’s exact.Experience or relief of psychotic-like experiences
Eleven percent of HR individuals reported experiencing
psychotic-like symptoms under the influence of sub-
stances and 10% reported using substances to help re-
lieve these experiences. All the HV denied psychotic-like
experiences under the influence of substances or using
substances to help relieve these symptoms.Discussion
The main aim of this study was to thoroughly describe
past and current substance use profiles of HR individuals
and compare them with a sample of healthy volunteers.
Results showed that, for overall substance use, the
prevalence of HR substance use was less or similar to
that of HV. The ony exception to this was past poly-
drug use, which was sightly higher for HR individuals,
although not statistically significant. HR poly-drug users
experimented with a wider range of substances than HV
poly-drug users. HR individuals were significantly youn-
ger than HV when they started using alcohol and drugs.
Choice of substance was similar when comparing HR
and HV individuals’ current and past use. Alcohol was
the most frequently reported substance used in both
groups. In terms of illicit substances, cannabis was the
most widely used drug in both groups. The use of other
illicit substances was considerably lower compared with
cannabis. The least used substances for both groups
were sedatives and opiates.g each substance for current and past mono-drug and
Past










0 8 21 0.010 22 17 0.436
9 2 2 1 22 16 0.327
0 0 1 6 2 0.272
1 1 1 6 4 0.743
0 1 1 3 3 1
0 0 1 1 0 1
3 1 0 1 15 9 0.254
Figure 1 Frequency of substance use in HR and HV individuals. (a) Current frequency of substance use (b) Past frequency of substance use.
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vealed that cannabis was the most commonly used sub-
stance [11], whereas in the present study it was alcohol.
Rates of use varied from 33% to 54%; this was consider-
ably higher than the 9% reporting cannabis use in the
present study. However, the prevalence of alcohol use
(46.5%) was greater than the highest reported rate in
other studies (17% - 44%).
Interestingly, none of the HR or HV individuals in-
cluded in this study could be categorised as suffering from
DSM-IV substance use disorder or dependence. This is
not only significantly different to the severity of use re-
ported in other HR samples [11], but also to a population-
based sample of individuals experiencing first-episode
psychosis from the same early intervention service [8].
In this cross sectional analysis cannabis abuse or de-
pendence and alcohol abuse or dependence was re-
ported in approximately 50% of CAMEO first episode
psychosis (FEP) patients. In addition, 38% disclosed poly
substance abuse and more than half of them used Class
A drugs. These findings were also replicated in FEP
samples from other countries [22].Therefore, the HR substance use profile in the present
sample was not only different to HV from the same geo-
graphical area, it also appears to differ from first-episode
psychosis patients in our region at the time of their re-
ferral to CAMEO. This is further substantiated by the
fact that after approximately 2 years of an antipsychotic-
free follow-up period for each individual at HR in this
sample, only 3 (5%) made a transition to a psychotic dis-
order. One possible conclusion to be drawn is that their
pattern of use could have some influence on psychotic-
like experiences but not on transition to a frank psychotic
disorder. Nevertheless, the frequent diagnosis of mood or
anxiety disorders in this sample supplicates the consider-
ation that substance use may also have had an impact
these outcomes. However, the cross-sectional design of
our study did not allow the consideration of the role sub-
stance use in the evolution of other non-psychotic psychi-
atric disorders.
The main difference between HR individuals and HV
was frequency of substance use. Current frequency of use
was significantly higher in HR individuals than HV for al-
cohol and cannabinoids. However, daily use of cannabis in
Russo et al. BMC Psychiatry  (2014) 14:361 Page 7 of 8our HR group (0%) was much lower than in other studies,
which found this frequency in around 60% of their HR
samples [23,24]. Cannabis use once to twice a week oc-
curred in 7% of our HR individuals in comparison to 20%
[23] and 19% [24] in previous studies. The one study that
reported frequency of alcohol use found similar drinking
behaviours in HR and HV individuals [25].
Notably, the frequency of substance use for HR individ-
uals, particularly for alcohol and cannabinoids, remained
similar for current and past use; whereas HV were more
likely to have a period in the past where they used these
substances more frequently. This could suggest that sus-
tained substance use over a protracted period could be
more deleterious than a shorter period of increased use.
Furthermore, the higher frequency of substance use in HR
individuals combined with a significantly younger age of
first use might eventually contribute to the development
of psychotic-like experiences.
The hypothesis that some individuals may use sub-
stances to alleviate psychotic symptoms [17] was not
supported in this study. In fact, very few HR individ-
uals reported using substances to help relieve these
experiences.
The results of this study must be considered in the light
of the following limitations. The multiple incidences of de-
pression and anxiety combined with the lack of transitions
may call in to question the authenticity of our HR sample.
However, co-morbidity of disorders of anxiety and depres-
sion with psychotic symptoms appears to be more preva-
lent than previously considered in adolescents and young
adults [3]. Added to this, the short follow-up in this study
could explain the low transition rate. Transitions can
occur up to 10 years after psychotic symptoms first
emerge [26]. Moreover, the 3 monthly follow-ups in this
study may have been therapeutic, indirectly providing
non-specific clinical care and consequently reducing the
likelihood of transition. Certainly, scrutiny of the follow-
up intervals in Addington’s review [11] revealed diverse
monitoring periods, in addition to varied transition rates.
Therefore, drawing valid conclusions on this issue is com-
plex. Also, the pattern of substance use was not closely
monitored for each individual after the time of their refer-
ral to CAMEO. Future research should address this limi-
tation since prospective follow-up could reveal changes in
patterns of substance use that could have an impact on
the incidence of psychotic experiences over time. The
small sample size of 60 participants is acknowledged.
However, this number is greater or comparable to over
half the studies in Addington’s review [11].
The sociodemographic differences in our sample com-
pared to other HR samples in the literature are also
potential limitations. Firstly, HV were significantly older
than HR individuals. However, the influence of this dis-
similarity in the domains that were significantly differentbetween both groups, i.e. age of first substance use and
frequency of substance use, was arguably negligible. Sec-
ondly, there is a geographical difference compared to
other research describing substance use in HR samples.
Although the majority of studies in Addington’s review
[11] were conducted in USA and Australia, several were
conducted in Europe. However, none were exclusively in
the UK. Despite the limitations of comparing such a di-
verse geographical spread of HR samples, describing
substance use in a UK sample of HR individuals provides
a useful contribution to the literature. Thirdly, although
there was some representation of different ethnicities,
the sample was predominantly white. Comparisons with
the existing literature on substance use in HR samples
are problematic as the majority of studies did not report
ethnicity or they dichotomised the categories e.g. white
vs non-white (see Addington et al. [11]). Finally, while
the gender ratio did not differ significantly between HR
and HV groups, the slightly higher proportion of males
in the HR group may have influenced the patterns of sub-
stance use, as male gender is associated with substance
use in patients and psychotic disorders in the general
population [27].
Conclusions
Research on individuals at HR is showing a remarkable
variability in clinical outcomes across different samples
worldwide. This is further corroborated by the difference
between the characteristics of the current HR sample
and other studies in this field. Although this is probably
due to a variety of factors, including both biological and
psychological components, certain profiles of substance
use could potentially play a significant part in the evolu-
tion of these presentations. Therefore, substance use may
well represent a clinical domain that requires further em-
phasis and more detailed consideration in future studies.
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